Bibliographic Details
| Title: |
THERAPEUTIC REGIMEN FOR TREATING CANCER |
| Document Number: |
20100305199 |
| Publication Date: |
December 2, 2010 |
| Appl. No: |
12/855050 |
| Application Filed: |
August 12, 2010 |
| Abstract: |
The invention provides a method for treating cancer in a human comprising administering to the human a dose of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) an adenoviral vector comprising a nucleic acid sequence encoding TNF-α operably linked to a promoter, wherein the dose comprises about 1×107 to about 4×1012 particle units (pu) of replication-deficient adenoviral vector, at least once in a therapeutic period comprising up to 10 weeks, whereby the cancer in human is treated. The invention further provides a method of treating a human for multiple tumors, wherein the method comprises contacting a first tumor with a dose of the pharmaceutical composition at least once in a therapeutic period comprising up to about 10 weeks, whereby the human is treated for the first tumor and one or more additional tumors. |
| Inventors: |
Rasmussen, Henrik S. (Arnold, MD, US); Chu, Karen W. (New York, NY, US) |
| Assignees: |
GenVec, Inc. (Gaithersburg, MD, US) |
| Claim: |
1. A method of treating a human for multiple tumors, wherein the method comprises directly administering to a first tumor a dose of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) an adenoviral vector comprising a nucleic acid sequence encoding TNF-α and operably linked to a promoter, wherein the dose comprises about 1×107 to about 4×1012 particle units (pu) of adenoviral vector, at least once in a therapeutic period comprising up to about 10 weeks, whereby the human is treated for the first tumor and one or more additional tumors. |
| Claim: |
2. The method of claim 1, wherein tumor cells within the first tumor and one or more additional tumors are destroyed. |
| Claim: |
3. The method of claim 2, wherein the size of the first tumor and one or more additional tumors is reduced. |
| Claim: |
4. The method of claim 3, wherein the adenoviral vector is replication-deficient. |
| Claim: |
5. The method of claim 4, wherein the method further comprises administering a dose of ionizing radiation to the tumor over the duration of the therapeutic period. |
| Claim: |
6. The method of claim 4, wherein the promoter is EGR-1. |
| Claim: |
7. The method of claim 1, wherein the dose of ionizing radiation comprises about 20 Grays (Gy) to about 70 Gy administered over the duration of the therapeutic period. |
| Claim: |
8. The method of claim 1, wherein the first tumor is a solid tumor. |
| Claim: |
9. The method of claim 8, wherein the first tumor is located in the breast, pancreas, colon, rectum, head, neck, brain, esophagus, or lung. |
| Claim: |
10. The method of claim 8, wherein the first tumor is located in the bladder, thyroid, mandible, skin, or kidney. |
| Claim: |
11. The method of claim 8, wherein the therapeutic period comprises up to six weeks, and the method comprises administering two doses of pharmaceutical composition in weeks 1-2 and one dose of pharmaceutical composition in each subsequent week of the therapeutic period. |
| Claim: |
12. The method of claim 8, wherein the pharmaceutical composition is administered to the first tumor via 2-5 injections. |
| Claim: |
13. The method of claim 1, wherein the first tumor is soft tissue sarcoma. |
| Claim: |
14. The method of claim 13, wherein the therapeutic period comprises about five weeks, and the method comprises administering two doses of pharmaceutical composition in week 1 and one dose of pharmaceutical composition in each subsequent week of the therapeutic period. |
| Claim: |
15. The method of claim 13, wherein the pharmaceutical composition is administered to the first tumor via 3-8 injections. |
| Claim: |
16. The method of claim 1, wherein the first tumor and the one or more additional tumors are located in different regions of the body of the human. |
| Current U.S. Class: |
514/44/R |
| Current International Class: |
61; 61 |
| Accession Number: |
edspap.20100305199 |
| Database: |
USPTO Patent Applications |
